Nutex Health is trading 8.19% up in pre-market at $164.37 after reporting a second-quarter 2026 earnings beat on August 6.
- Diluted EPS reached $9.38, versus a year-ago loss of $2.95; net income rose to $65.8 million.
- The beat was driven largely by lower arbitration-related expenses, including a $52.3 million retroactive reduction tied to a HaloMD contract amendment.
- Management reaffirmed full-year revenue guidance of $885.7 million.